Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
|Videos|August 24, 2016
David Dubin on When to Look for Lynch Syndrome
Author(s)David Dubin
Dave Dubin, founder of AliveAndKickn, discusses the importance of healthcare professionals knowing when to test for Lynch syndrome.
Advertisement
Dave Dubin, founder of AliveAndKickn, discusses the importance of healthcare professionals knowing when to test for Lynch syndrome.
One of the goals of AliveAndKickn is to educate clinicians about when to test for Lynch syndrome. They should know that Lynch syndrome could cause a variety of cancers at any given time, and perhaps a patient coming in with colon cancer should not only be treated solely for the specific tumor type, but also be tested, if appropriate, for the genetic mutation.
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
3
Male Breast Cancer: Warning Signs, Biology, and Genetic Testing
4
Making Innovation Meaningful: Enabling Personalized Care in Multiple Myeloma
5